1 / 5

Dr. Michael Har-Noy’s AlloStimTM Is Scaleable While CAR-T Cells Are Not

Dr. Michael Har-Noy plans to start a pivotal Phase II/III randomized study of AlloStimTM in the therapy of metastatic KRAS gene positive colon tumors. Dr. Michael Har-Noy notes there is no approved third line treatment for these patients. A favorable outcome of this study would likely lead to FDA marketing approval for AlloStimTM. Dr. Michael Har-Noy intends to start the study in the United States as well as two other international sites.

Download Presentation

Dr. Michael Har-Noy’s AlloStimTM Is Scaleable While CAR-T Cells Are Not

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Dr. Michael Har-Noy’sAlloStimTM Is ScaleableWhile CAR-T Cells Are Not Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd., biotech company in Israel, says that CAR-T therapy for a cancer patient must be produced using the patient’s own tumor cells and thus cannot be manufactured on a large scale.

  2. Dr. Michael Har-Noy Notes That CAR-T Therapy Appears Less Effective In Solid Tumors Dr. Michael Har-Noy of Immunovative Therapies, Ltd. points out that early research indicates that CAR-T treatment has limited effectiveness in treating solid malignancies. Also, CAR-T therapy frequently causes serious toxic reactions. Dr. Michael Har-Noy notes that Immunovative Therapies, Ltd.’s AlloStimTM seems to have activity against most tested solid tumors. Dr. Michael Har-Noy says he will soon publish a Phase I/II study involving AlloStimTM treatment. Dr. Michael Har-Noy adds that unlike CAR-T therapy, AlloStimTM can be made in large amounts from any healthy donor’s blood. Therefore, AlloStimTM can be inexpensively produced in virtually unlimited quantities.

  3. Dr. Michael Har-Noy Discusses AlloStimTM and Checkpoint Blockade Treatment Dr. Michael Har-Noy of Immunovative Therapies, Ltd. says that checkpoint blockade compounds interfere with molecules that malignant cells use to hide from a patient’s immune system. Yervoy and Opdivo are such checkpoint blockade drugs. Dr. Michael Har-Noy says, however, that checkpoint blockade agents work only if the patient has an intact immune response.

  4. Dr. Michael Har-Noy Will Soon Start A Phase II/III Trial In Colorectal Tumors Dr. Michael Har-Noy plans to start a pivotal Phase II/III randomized study of AlloStimTM in the therapy of metastatic KRAS gene positive colon tumors. Dr. Michael Har-Noy notes there is no approved third line treatment for these patients. A favorable outcome of this study would likely lead to FDA marketing approval for AlloStimTM.

  5. https://www.smore.com/qump-michael-har-noy

More Related